Drug combination for advanced lung cancer in older adults
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of two drugs (bempemab and anlotinib) as a first treatment for older adults with advanced lung cancer. The goal is to see if this drug pair can shrink tumors and slow the cancer, possibly without the need for chemo or radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 75 years old or older
- You have non-small-cell lung cancer that has spread or is locally advanced and cannot be treated with surgery or standard chemo-radiation
- Your cancer does not have certain gene changes (EGFR or ALK) that would allow a different targeted pill
- You cannot tolerate or have decided against chemotherapy or radiation
- You have at least one tumor that can be measured on a scan
- Your overall health is good enough to walk and care for yourself (ECOG score 0-2)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs—anlotinib, benmelstobart, and chemotherapy—as a first treatment for pancreatic cancer that has spread. The goal is to see if this combo can shrink tumors or slow the cancer's growth better than current options.
This study tests a combination of two targeted therapy pills (andamertinib and anlotinib) for people with a specific type of lung cancer (EGFR-mutant NSCLC) that has progressed after taking a previous targeted therapy. The goal is to see if this new combination can stop the cancer from growing.
This trial tests a new combination of drugs and radiation to improve the effects of first-line chemotherapy and immunotherapy for patients with advanced non-small cell lung cancer that has spread to the bones. The goal is to help shrink tumors and potentially improve overall outcomes.
This trial tests a new combination of two medications (SKB264 and anlotinib) for people with advanced non-small cell lung cancer that has spread to the liver and no longer responds to a standard pill called an EGFR-TKI. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests a new combination of two drugs, anlotinib and benmelstobart, for people with advanced esophageal squamous cell carcinoma that has not been treated before or has come back after more than six months. The goal is to see if this combination can help control the cancer and improve outcomes.
This trial is testing a combination of three drugs (benmelstobart, anlotinib, and chemotherapy) as the first treatment for people with a rare type of cancer called LCNEC or EP-NEC that has spread. The goal is to see if this combination can help shrink or control the cancer and improve outcomes.
Hear when a new Locally Advanced Non-Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.